Integrated Nanotherapeutics Inc.

Integrated Nanotherapeutics Inc (INT) is a preclinical company developing antigen specific immune tolerance therapies using mRNA-Lipid nanoParticles (LNP). We have demonstrated that our mRNA-LNP therapy can reverse Type 1 Diabetes (T1D) in NOD mice. We were recently awarded a grant from Breakthrough T1D (formerly JDRF). With a growing pipeline in other T-cell-driven autoimmune diseases, we have successfully demonstrated in additional animal models that our tolerizing-LNP induces antigen-specific immune tolerance. Our proprietary technologies allow the incorporation of any compound in lipid nanoparticle delivery systems and thus extend the benefits of delivery systems to virtually any therapeutic and diagnostic agent. We envision that many existing drugs or agents can be made much safer and more effective using our technologies. We leverage this inherent capability of our platform technology to achieve antigen specific immune tolerance. We can deliver multiple antigens or epitopes due to the simplicity of using mRNA to express them. Additionally, we modify the immune response phenotype to these antigens by incorporating small-molecule immune modulators within the same LNP package.